This study suggested that the National Comprehensive Cancer Network Distress Thermometer problem list does not easily identify concerns most associated with high distress and low quality of life in women with gynecologic cancers.
These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.
Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers.
COX7RP contributes to endometrial and breast cancer growth.
Diagnosis of endometrial carcinoma made easier by analysis of mutations in cervix or endometrial tissue.
A study recently published in the Journal of Clinical Oncology reported on the association between power morcellation and mortality in women with unexpected uterine cancer who were undergoing a hysterectomy or myomectomy.
Immunotherapy could replace chemotherapy in some patients with recurrent/metastatic cervical and vaginal or vulvar cancers.
Researchers examined the results of ribociclib and letrozole as a treatment for patients with estrogen receptor-positive ovarian cancer and endometrial cancer.
The US Food and Drug Administration recently approved a new indication for olaparib for maintenance treatment in adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer.
How much do you know about predicting patient outcomes in ovarian cancer? Take our latest quiz to test your knowledge.